Stoke Therapeutics Announces Presentations Related to the Company’s Work to Advance STK-001, the First Potential New Medicine to Target the Underlying Cause of Dravet Syndrome at the American Epilepsy Society (AES) 2020 Annual Meeting
The Pharma Data
DECEMBER 3, 2020
The disease is classified as a developmental and epileptic encephalopathy due to the developmental delays and cognitive impairment associated with the disease. Reducing the Time to Diagnosis and Increasing the Detection of Individuals with SCN1A- related Disease Through a Sponsored Epilepsy Genetic Testing Program.
52 
Let's personalize your content